Amneal Pharmaceuticals
440 U.S. Highway 22 East
Suite 104
Bridgewater
New Jersey
08807
United States
Tel: 908-947-3120
Fax: 908-947-4146
Website: http://www.amneal.com/
275 articles about Amneal Pharmaceuticals
-
Amneal to Report First Quarter 2023 Results on May 5, 2023
4/12/2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2023 financial results on Friday May 5, 2023, prior to market open.
-
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
3/2/2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the fourth quarter and full year ended December 31, 2022.
-
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
3/2/2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan® and is used in the treatment of a known or suspected opioid overdose emergency.
-
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
1/31/2023
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open.
-
Amneal Announces Strategic European Partnership with Orion Corporation
1/4/2023
Amneal Pharmaceuticals, Inc. announced it has signed a long-term license agreement with Orion Corporation to commercialize a number of Amneal’s complex generic products.
-
Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand
1/4/2023
Orion Corporation announced it has signed a long-term license agreement with Amneal Pharmaceuticals, Inc. to commercialise Amneal’s generic products in Orion territories.
-
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
12/20/2022
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval.
-
Amneal to Participate at Upcoming Investor Conferences
11/23/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that the management team will attend the following investor conferences.
-
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States
11/22/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of RELEUKO® (filgrastim-ayow), a biosimilar referencing Neupogen®.
-
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
11/11/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for IPX203 for the treatment of Parkinson’s disease.
-
Amneal Reports Third Quarter 2022 Financial Results
11/4/2022
Amneal Pharmaceuticals, Inc. announced its results for the third quarter ended September 30, 2022.
-
Amneal Receives FDA Approval for Leuprolide Acetate Injection
11/2/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for leuprolide acetate for injection.
-
Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory
10/31/2022
Amneal Pharmaceuticals, Inc. announced it has appointed Reem Malki as Senior Vice President, Chief Quality Officer, and Maryll W. Toufanian as Senior Vice President, Regulatory Strategy and Policy.
-
ImmunityBio is laying off 38 employees at its Dunkirk site in New York, Amneal will shutter a Long Island facility and Rigel culls 30 employees following wAIHA regulatory decision.
-
Amneal to Report Third Quarter 2022 Results on November 4, 2022
10/6/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its third quarter 2022 financial results on Friday November 4, 2022, prior to market open.
-
Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States
10/3/2022
First of three approved U.S. oncology biosimilars Amneal expects to launch Amneal Pharmaceuticals, Inc. announced the commercial launch of ALYMSYS®, a biosimilar referencing Avastin®.
-
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty
9/6/2022
Amneal Pharmaceuticals, Inc. announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022.
-
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease
8/31/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease (PD).
-
Amneal supports Congress’ efforts to ensure essential medicines are Made in America
8/22/2022
Amneal Pharmaceuticals, Inc. announced its support of the creation of the bipartisan Congressional Domestic Pharmaceutical Manufacturing Caucus.
-
Amneal launches 4 new Generic products, including Vasopressin single-dose
8/11/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for four generics products, including vasopressin injection 1mL (single-dose).